Abbott is preparing to train centers to treat severe tricuspid valve regurgitation with its TriClip G4 transcatheter edge-to-edge repair device now that US regulatory approval in 2024 is all but assured.
Wall Street analysts expect the US Food and Drug Administration to approve TriClip G4 in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?